Concepedia

Bonnie K. Harrington

BK

Statistics

Publications

30

Citations

2.9K

H-Index

24

Active since

1985

Affiliations

The Ohio State University(Current)

Michigan State University

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Dana-Farber Cancer Institute

Karyopharm Therapeutics (United States)

Bonnie K. Harrington is an author at The Ohio State University specializing in medicine, oncology, and pharmacology.

Publications per year

1985–2024

30

Publications

30

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert et al. · Blood · 2013 · 219 citations

Medicine, Hematology, Oncology +15

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Jason A. Dubovsky, Ryan Flynn, Jing Du et al. · Journal of Clinical Investigation · 2014 · 199 citations

Life Sciences, Immunology, Pharmacotherapy +16

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

Andrew Stiff, Prashant Trikha, Robert Wesolowski et al. · Cancer Research · 2016 · 183 citations · Full text

Medicine, Oncology, Pharmacology +16

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Sean D. Reiff, Rose Mantel, Lisa L. Smith et al. · Cancer Discovery · 2018 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 30